DIAPREV-IT study of diabetes therapy Diamyd® receives further funding and will continue despite disappointing Phase III trial results

Immunotherapy. 2011 Aug;3(8):923-4. doi: 10.2217/imt.11.103.
No abstract available

Publication types

  • News

MeSH terms

  • Animals
  • Autoantigens / immunology*
  • Child
  • Clinical Trials, Phase III as Topic
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 1 / immunology
  • Disease Progression
  • Europe
  • Financial Support
  • Glutamate Decarboxylase / immunology*
  • Humans
  • Treatment Outcome
  • Vaccination

Substances

  • Autoantigens
  • Glutamate Decarboxylase
  • glutamate decarboxylase 2